• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Platelet Rich Plasma Injections Are Not Beneficial for Acute Hamstring Injuries

July 11, 2014

Platelet rich plasma (PRP) is a plasma component that is enriched with platelets. Within the past 15 years, PRP use has increased to treat patients with tendon, cartilage, ligament or muscle injury, since platelets have granules which contain cytokines and growth factors and may aid in wound healing.

Evidence, however, from randomized trials is lacking that PRP actually speeds injury recovery. A recent double-blind, placebo-controlled trial published in the New England Journal of Medicine tested the efficacy of PRP injections versus saline in 80 patients with acute hamstring muscle injuries. There were no substantial differences between the trial arms.  Both groups had similar median times (42 days) until they could resume their sport activities. Re-injury rates were also similar in both groups (16% in the PRP group and 14% in the placebo group), and no serious adverse events occurred throughout the six month trial.  Further exploration of the efficacy of PRP treatment in sports-related injuries is warranted.

Reference
1. Reurink G, Goudswaard GJ, Moen MH, Weir A, Verhaar JA, Bierma-Zeinstra SM, Maas M, Tol JL, Dutch Hamstring Injection Therapy Study I. Platelet-rich plasma injections in acute muscle injury. N Engl J Med 2014;370: 2546-7.

 

Filed Under

  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Donor Interventions Increase Donor’s Return for Future Donations

  • Recombinant Thrombomodulin for Treatment of Transplant-Associated Thrombotic Microangiopathy

  • Demographic Changes Directly Impact Blood Supply, but Not Demand

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley